E
3.74
0.12 (3.31%)
| Previous Close | 3.62 |
| Open | 3.60 |
| Volume | 102,243 |
| Avg. Volume (3M) | 82,904 |
| Market Cap | 191,133,456 |
| Price / Book | 1.36 |
| 52 Weeks Range | |
| Earnings Date | 10 Sep 2025 - 25 Sep 2025 |
| Diluted EPS (TTM) | -1.63 |
| Total Debt/Equity (MRQ) | 11.16% |
| Current Ratio (MRQ) | 12.66 |
| Operating Cash Flow (TTM) | -75.39 M |
| Levered Free Cash Flow (TTM) | -47.37 M |
| Return on Assets (TTM) | -20.35% |
| Return on Equity (TTM) | -33.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | enGene Holdings Inc. | Bullish | Bearish |
AIStockmoo Score
2.1
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 13.63% |
| % Held by Institutions | 77.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (HC Wainwright & Co., 568.45%) | Buy |
| Median | 21.50 (474.87%) | |
| Low | 18.00 (Morgan Stanley, 381.28%) | Buy |
| Average | 21.50 (474.87%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Sep 2025 | 25.00 (568.45%) | Buy | 6.06 |
| 08 Sep 2025 | 25.00 (568.45%) | Buy | 5.43 | |
| Morgan Stanley | 12 Sep 2025 | 18.00 (381.28%) | Buy | 6.06 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jul 2025 | Announcement | enGene Announces Board and Leadership Appointments to Support Commercial Readiness |
| 25 Jun 2025 | Announcement | FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer |
| 17 Jun 2025 | Announcement | enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |